The Group

KINGSPAN ACHIEVES 26% REDUCTION IN ABSOLUTE SCOPE 1 & 2 EMISSIONS SINCE 2020

Retrieved on: 
Tuesday, March 7, 2023

The starting price will be 70€/tCO₂e (scope 1&2 GHG emissions, excluding process and biogenic emissions).

Key Points: 
  • The starting price will be 70€/tCO₂e (scope 1&2 GHG emissions, excluding process and biogenic emissions).
  • Gene Murtagh, CEO of Kingspan Group, said: 'As a Group, Kingspan remains steadfast in our commitment to help accelerate progress towards a net zero emissions future.
  • Since 2020, we have reduced our absolute scope 1 &2 GHG emissions by 26%, doubled our rainwater harvesting capacity and reduced our landfill waste by 42%.
  • [1] Refers to the estimated lifetime in-use emissions savings benefit from Kingspan insulation systems sold in 2022.

KINGSPAN ACHIEVES 26% REDUCTION IN ABSOLUTE SCOPE 1 & 2 EMISSIONS SINCE 2020

Retrieved on: 
Tuesday, March 7, 2023

The starting price will be 70€/tCO₂e (scope 1&2 GHG emissions, excluding process and biogenic emissions).

Key Points: 
  • The starting price will be 70€/tCO₂e (scope 1&2 GHG emissions, excluding process and biogenic emissions).
  • Gene Murtagh, CEO of Kingspan Group, said: 'As a Group, Kingspan remains steadfast in our commitment to help accelerate progress towards a net zero emissions future.
  • Since 2020, we have reduced our absolute scope 1 &2 GHG emissions by 26%, doubled our rainwater harvesting capacity and reduced our landfill waste by 42%.
  • [1] Refers to the estimated lifetime in-use emissions savings benefit from Kingspan insulation systems sold in 2022.

First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases

Retrieved on: 
Friday, February 10, 2023

Previously, the first patients in the European Union (EU) and Australia were dosed in the same global multicenter phase 3 clinical trial of EB12-20145P (HLX04-O).

Key Points: 
  • Previously, the first patients in the European Union (EU) and Australia were dosed in the same global multicenter phase 3 clinical trial of EB12-20145P (HLX04-O).
  • Meanwhile, the first patient has been dosed in a parallel phase 3 clinical trial in China for EB12-20145P (HLX04-O) for the treatment of wAMD.
  • This randomised, double-blinded, active-controlled, global phase 3 study aims to compare the efficacy and safety of EB12-20145P (HLX04-O) with ranibizumab in patients with wet age-related macular degeneration (wAMD).
  • EB12-20145P (HLX04-O) has the potential to be one of the first bevacizumab approved for use in ophthalmic diseases, benefiting more patients with eye diseases worldwide.

SEMK takes on new name "B.Duck Semk Holdings International Limited"

Retrieved on: 
Wednesday, February 8, 2023

In 2021, B.Duck topped all Chinese original IPs in the domestic IP licensing market in terms of revenue.

Key Points: 
  • In 2021, B.Duck topped all Chinese original IPs in the domestic IP licensing market in terms of revenue.
  • It is not easy for a relatively young brand like B.Duck to earn a place in the talent-abundant IP market.
  • The Group will also develop a unique style guide, derivative product design, and licensing business expansion for its partners' IP.
  • B.Duck Semk will relentlessly make new attempts and pursue different creative tracks, in its bid to become an evergreen IP brand."

SF Intra-City's H share full circulation expected to complete 78.95 million unlisted domestic shares to be listed on 7 February

Retrieved on: 
Friday, February 3, 2023

Upon completion of the conversion and listing, the Company's total number of H shares will be increased from 231,341,342 to 310,289,026, representing an increase in the approximate percentage of issued H shares from 24.78% to 33.24% of the Company's total number of shares.

Key Points: 
  • Upon completion of the conversion and listing, the Company's total number of H shares will be increased from 231,341,342 to 310,289,026, representing an increase in the approximate percentage of issued H shares from 24.78% to 33.24% of the Company's total number of shares.
  • H share full circulation is also expected to promote the Group's long-term development by reducing the mismatch between the market capitalisation of its shares and the size of its business.
  • The Company believes that H share full circulation will enhance capital allocation demand for its shares and boost its valuation, which will benefit the Company's development and shareholders' interests in the long run.
  • The positive news regarding the H share full circulation follows the Group's recent announcement of a more than 50% year-on-year reduction in its loss for the financial year 2022.

RETAIL HOLDINGS N.V. ANNOUNCES 2022 RESULTS

Retrieved on: 
Thursday, January 12, 2023

WILLEMSTAD, Curacao, Jan. 12, 2023 /PRNewswire/ -- Retail Holdings N.V. (Symbol: RHDGF) - Retail Holdings N.V. (the "Company", together with its subsidiaries, the "Group"), announced today results for the year ended December 31, 2022 and updated the Company's liquidation effort. 

Key Points: 
  • WILLEMSTAD, Curacao, Jan. 12, 2023 /PRNewswire/ -- Retail Holdings N.V. (Symbol: RHDGF) - Retail Holdings N.V. (the "Company", together with its subsidiaries, the "Group"), announced today results for the year ended December 31, 2022 and updated the Company's liquidation effort.
  • Following the divestment of the India business in December 2021, the Group has no remaining continuing operations.
  • For the year ended December 31, 2022, the loss from Discontinued operations, net of taxes, was $439 thousand.
  • The loss attributable to the Company's shareholders is $373 thousand for the year ended December 31, 2022, compared to an attributable loss of $259 thousand for the same period prior year.

SF Intra-City reduced losses by over 50% year-over-year in 2022, Increasing benefits from scale effect

Retrieved on: 
Monday, January 30, 2023

These results reflect the increasingly apparent benefits of the Group's diversified service landscape and technology-driven efficiency improvements.

Key Points: 
  • These results reflect the increasingly apparent benefits of the Group's diversified service landscape and technology-driven efficiency improvements.
  • With the accelerated development of Douyin's live e-commerce ecosystem, this segment will contribute considerable incremental order volume to SF Intra-City in the future.
  • As the largest third-party on-demand delivery service platform in China, the Group continues to achieve benefits from the scale effect, and both the fundamentals and the overall trend continue to improve, driving stronger earnings performance.
  • We firmly believe in the long-term value of local lifestyle services and on-demand services, and we will strive to achieve profitability and create long-term value for our shareholders."

Ching Lee Holdings (3728.HK) Wins in Adversity, Committed to Improving Cost Efficiency

Retrieved on: 
Monday, January 9, 2023

HONG KONG, Jan 9, 2023 - (ACN Newswire) - Ching Lee Holdings Limited "Ching Lee" or "The Group" (stock code 3728.HK) recorded over 20% increase in gross profit in the latest interim results ended 30 September 2022 benefiting from the total reinforcement of cost control.

Key Points: 
  • HONG KONG, Jan 9, 2023 - (ACN Newswire) - Ching Lee Holdings Limited "Ching Lee" or "The Group" (stock code 3728.HK) recorded over 20% increase in gross profit in the latest interim results ended 30 September 2022 benefiting from the total reinforcement of cost control.
  • Ching Lee has always taken a prudent attitude toward the Group's operations, actively strengthening project cost control and saving administrative and operating expenses.
  • Even during the difficult epidemic period, Ching Lee strives to fight against adversity and insists on bringing benefits to shareholders.
  • Two large-scale projects in Stanley and Tsim Sha Tsui were completed in 2022 and other projects will be completed continuously.

Shares of Major Global Medical Device Manufacturer OrbusNeich Medical Group Commence Trading on the Main Board of The Stock Exchange of Hong Kong

Retrieved on: 
Friday, December 23, 2022

HONG KONG, Dec 23, 2022 - (ACN Newswire) - Shares of OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"), a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("HKEX"), under the stock code 6929.

Key Points: 
  • HONG KONG, Dec 23, 2022 - (ACN Newswire) - Shares of OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"), a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("HKEX"), under the stock code 6929.
  • Mr. Teddy Chien, Chairman Emeritus and Founder (right) and Mr. David Chien, Chairman, Executive Director, Chief Executive Officer (left), together strike the ceremonial gong, marking the Group's listing on the Main Board of HKEX
    OrbusNeich makes a generous donation of HK$3,000,000 to HKEX Foundation to secure the auspicious stock code number "6929".
  • Mr. David Chien, Chairman, Executive Director, Chief Executive Officer (right) presents the cheque to HKEX
    (From left to right): John Chow,Executive Director and Head of Business Development; Jason Chen, Executive Director, Chief Financial Officer and Company Secretary; Gloria Tam, Independent Non-executive Director; Denise Lau, Executive Director and Chief Operating Officer; Teddy Chien, Chairman Emeritus and Founder; David Chien, Chairman, Executive Director and Chief Executive Officer; George Lau, Independent Non-executive Director; Angus Chan, Independent Non-executive Director

SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards"

Retrieved on: 
Monday, December 19, 2022

SinoMab was awarded the "Most Valuable Pharmaceutical and Medical Company", highlighting the attention and recognition of the industry and investors on the Company's value and innovation capabilities, which is a great encouragement and even a spur to SinoMab.

Key Points: 
  • SinoMab was awarded the "Most Valuable Pharmaceutical and Medical Company", highlighting the attention and recognition of the industry and investors on the Company's value and innovation capabilities, which is a great encouragement and even a spur to SinoMab.
  • SinoMab is the first Hong Kong-based listed biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics, primarily monoclonal antibody ("mAb")-based biologics, for the treatment of immunological diseases.
  • Currently, various candidate products for all-field indications of autoimmune diseases in SinoMab's layout have started clinical trials successively and are progressing steadily.
  • Previously, SinoMab appointed Mr. Shanchun WANG as the President (China) of the Company, mainly responsible for the China operation.